Nexthera Capital’s Atara Biotherapeutics ATRA Stock Holding History

Nexthera Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,466	Closed	-$5.19M	–	43
2017 Q4	$5.19M	Buy	+11,466	New	+$4.23M	0.96%	26

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nexthera Capital's ATRA Position: Q1 2018 in Review

Nexthera Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2018, closing a stake of 11,466 shares — an estimated $5.19M sold.

Nexthera Capital first reported a position in ATRA in Q4 2017 and held it in 1 quarter. The position peaked at $5.19M in Q4 2017. 114 funds tracked by Wall St. Rank hold ATRA as of Q1 2018.

Nexthera Capital reported no remaining Atara Biotherapeutics position as of Q1 2018 after selling out during the quarter.
Nexthera Capital sold 11,466 Atara Biotherapeutics shares in Q1 2018, an estimated $5.19M.
Nexthera Capital first reported a position in Atara Biotherapeutics in Q4 2017 and held it in 1 quarter.
Nexthera Capital's Atara Biotherapeutics position peaked at $5.19M in Q4 2017.
114 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2018.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.